PPBT Stock Risk & Deep Value Analysis
Purple Biotech Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PPBT Stock
We analyzed Purple Biotech Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PPBT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PPBT Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk remains clinical trial failure for the CAPTN-3 platform or inability to secure meaningful partnerships for CM24/NT219. This would likely necessitate further dilutive financing, significantly eroding shareholder value even with the currently extended cash runway.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Company remains pre-revenue with significant cash burn, requiring future funding.
- ⚠
CEO transition introduces some uncertainty during a critical development phase.
- ⚠
High reliance on future clinical success and non-dilutive partnerships for value creation.
Upcoming Risk Events
- 📅
Negative or inconclusive GLP toxicology results for CAPTN-3
- 📅
Delay in IND submission or Phase 1 initiation for CAPTN-3
- 📅
Inability to secure partnerships for CM24/NT219 by H2 2027
When to Reconsider
- 🚪
Failure to meet IND/Phase 1 timelines for CAPTN-3 by more than two quarters.
- 🚪
Announcement of highly dilutive financing (>30% dilution for existing shareholders).
- 🚪
Significant negative clinical data for any pipeline asset.
Unlock PPBT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Purple Biotech Ltd (PPBT) Do?
Market Cap
$6.05M
Sector
Healthcare
Industry
Biotechnology
Employees
9
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Visit Purple Biotech Ltd WebsiteInvestment Thesis
Purple Biotech is a high-risk, high-reward oncology biotech with a diversified pipeline, including a novel tri-specific antibody platform (CAPTN-3) poised for clinical entry and two Phase 2 assets ready for partnerships. The recent extension of its cash runway into H1 2027 provides a critical window to achieve key de-risking milestones and secure non-dilutive funding, potentially enabling a significant re-rating from its current micro-cap valuation within 3-5 years.
Is PPBT Stock Undervalued?
Unlock the full AI analysis for PPBT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PPBT Price Targets & Strategy
12-Month Target
$50.00
Bull Case
$80.00
Bear Case
$2.00
Valuation Basis
Target reflects ~12x current price, implying a market capitalization of $46.5 million based on successful IND filing and Phase 1 initiation for CAPTN-3, alongside a minor non-dilutive partnership for existing Phase 2 assets. This is a common valuation for early-stage oncology biotechs with validated platforms/assets.
Entry Strategy
Dollar-cost average at current levels ($4-$5) and on any dips, given the highly speculative nature. Look for support around previous trading lows if available.
Exit Strategy
Take partial profits at $40-$50 if clinical milestones are met, re-evaluate upon Phase 1 data for CAPTN-3 or significant partnership announcements. Stop-loss at $2.50 to protect against further downside from clinical setbacks or significant dilution.
Portfolio Allocation
2-4% for aggressive risk tolerance, only as part of a highly diversified biotech portfolio.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does PPBT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability depends entirely on the successful clinical development of its drug candidates and the strength of its intellectual property. Success in clinical trials will validate its platform and compounds, strengthening its competitive position.
Moat Erosion Risks
- •Clinical trial failures for lead assets or the CAPTN-3 platform
- •Intense competition from larger pharmaceutical companies or other innovative biotechs
- •Patent challenges or expiry reducing IP protection
PPBT Competitive Moat Analysis
Sign up to see competitive advantages
PPBT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Limited data available)
Institutional Sentiment
Neutral (No analyst coverage or institutional ownership disclosed)
Insider Activity (Form 4)
Agmon Ido (Director) and Shai S. Lankry (CFO) hold significant beneficial ownership via shares, RSUs, and stock options, indicating alignment. No recent Form 4 buy/sell transactions reported in the last 90 days.
Options Flow
Normal options activity (No specific unusual options flow data available)
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026 results)
Surprise Probability
Low
Historical Earnings Pattern
No historical earnings reaction patterns are available given the company's early stage and limited financial reporting.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in research, generally small-to-mid cap oncology biotechs with novel platforms (e.g., ADCT, IMAB)
Market Share Trend
Too early-stage to assess market share trends; currently focused on drug development and clinical validation.
Valuation vs Peers
Trading at a very low market capitalization ($3.85M based on current price and shares outstanding), which implies significant upside if clinical milestones are met, but also reflects high risk compared to more established oncology biotechs.
Competitive Advantages
- •Proprietary CAPTN-3 tri-specific antibody platform technology
- •Clinical-stage assets (CM24, NT219) targeting specific unmet needs
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PPBT Stock Higher?
Near-Term (0-6 months)
- •CEO transition to new leadership (August 2026)
- •GLP toxicology planned for CAPTN-3 (Q3 2026)
- •IND submission for CAPTN-3 (Q4 2026)
Medium-Term (6-18 months)
- •First-in-human Phase 1 initiation for CAPTN-3 (Q1 2027)
- •Strategic partnership announcements for CM24 and/or NT219
Long-Term (18+ months)
- •Positive Phase 1/2 clinical data for CAPTN-3 platform
- •Pipeline expansion with additional CAPTN-3 candidates
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PPBT?
- ✓
Successful progression of CAPTN-3 into Phase 1 clinical trials
- ✓
Announcement of licensing deals or strategic partnerships for CM24/NT219
- ✓
Positive updates on the company's cash position and runway
Bull Case Analysis
See what could go right with Premium
Competing with PPBT
See how Purple Biotech Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Purple Biotech Ltd PPBT | $6.0M | 6.6 | — | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Purple Biotech Ltd Makes Money
Purple Biotech is an oncology-focused biotech company that develops novel therapeutic candidates, primarily for hard-to-treat cancers. It operates an R&D-intensive model, aiming to advance drug candidates through pre-clinical and clinical trials. Its primary goal is to either license out successful drug candidates to larger pharmaceutical companies for further development and commercialization, or to secure strategic partnerships that provide funding and potentially lead to royalty revenues. The company's current value creation relies heavily on achieving clinical milestones and demonstrating the efficacy and safety of its pipeline assets.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Purple Biotech Ltd (PPBT)?
As of April 7, 2026, Purple Biotech Ltd has a DVR Score of 6.6 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Purple Biotech Ltd?
Purple Biotech Ltd's market capitalization is approximately $6.0M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Purple Biotech Ltd use?
PPBT is the ticker symbol for Purple Biotech Ltd. The company trades on the NCM.
What is the risk level for PPBT stock?
Our analysis rates Purple Biotech Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Purple Biotech Ltd's revenue growing?
Purple Biotech Ltd has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is PPBT stock profitable?
Purple Biotech Ltd has a profit margin of 0.0%. The company is currently unprofitable.
How often is the PPBT DVR analysis updated?
Our AI-powered analysis of Purple Biotech Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 7, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PPBT (Purple Biotech Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.